Burns James William 4
4 · AGIOS PHARMACEUTICALS, INC. · Filed Jun 26, 2025
Insider Transaction Report
Form 4
Burns James William
Chief Legal Officer
Transactions
- Sale
Common stock
2025-06-24$33.54/sh−2,799$93,878→ 28,650 total - Exercise/Conversion
Performance share units
2025-06-24−6,000→ 6,000 total→ Common stock (6,000 underlying) - Exercise/Conversion
Common stock
2025-06-24+6,000→ 31,449 total
Footnotes (3)
- [F1]Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's performance share unit agreement dated March 1, 2023.
- [F2]Each performance share unit represents a contingent right to receive one share of the issuer's common stock.
- [F3]The PSUs were granted on March 1, 2023. The PSUs vest as to 50% of the underlying shares upon the achievement of a specified research milestone and as to the remaining 50% of the underlying shares upon the achievement of a specified regulatory milestone. The performance criteria for the specified research milestone was determined to have been met on June 24, 2025, resulting in the vesting of the PSUs as to 50% of the underlying shares. Vested shares will be delivered to the reporting person within three business days after such shares become vested.